Company Analysis

Universe Pharmaceuticals Inc. (UPC)

Nasdaq: UPC · Pharmaceutical Preparations · Ji'An, Jiangxi, CN · filing with the SEC since 2020
Grade6.0
◀ Past 6.0● Present 6.7▶ Future 5.1
2 est.
The companyfiscal 2025, as filed
Revenue$17.86B-22.4%
Net income-$3.67B+57.9%
Earnings per share$-8.06+99.4%
Operating cash flow-$5.05B+46.9%
Cash$33.59B+13.9%
Debtn/a
Shareholders’ equity$56.13B+23.4%
Shares, dilutedn/a
Return on equity-6.5%
The recordfrom its filings
Filings in 202629
Newest filingOct 9 · EFFECT
Annual reportJan 29, 2026
Quarterly reportn/a
Next report due20-F by Jan 28
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 9, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Sep 1, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Sep 1, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Sep 1, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Sep 1, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Sep 1, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Sep 1, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton UPC · research, not advice